InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,240.03
(
1.04%
)
US TECH 100
17,508.00
(
0.54%
)
Dow Jones
38,997.66
(
0.76%
)
Brent Oil
76.20
(
-1.24%
)
Bitcoin
56,273.95
(
4.22%
)
Post# of 13962
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Tome1310

Send PM Follow Ignore
Followers 0
Posts 86
Boards Moderated 0
Alias Born 02/04/2019

Tome1310

Re: Tome1310 post# 2932

Sunday, 02/17/2019 8:36:09 PM

Sunday, February 17, 2019 8:36:09 PM

Post# of 13962
If anyone was interested in the company or they even thought they could sell, then Extera would not be needed and the higher ups would have kept more stock instead of dumping most of them. The deal with vector was only for maybe 18 million for Ceplene. Not much for a drug. And they aren't even out of phase 2 yet with Bertilimumab! It is been in phase 2 for seven years+! Lol The options that fell apart were the last kick at the horse. The horse is dead.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up